Breaking News Instant updates and real-time market news.

ADAP

Adaptimmune

$6.40

-0.39 (-5.74%)

18:07
10/09/16
10/09
18:07
10/09/16
18:07

Adaptimmune reports data on NY-ESO SPEAR T-cell receptor therapy

Adaptimmune Therapeutics announced a presentation of updated data on its lead clinical program, an NY-ESO SPEAR T-cell receptor therapy, in patients with synovial sarcoma at the European Society for Medical Oncology 2016 Congress. The study included Cohort 1: Subjects with high NY-ESO-1 antigen expression and lymphodepletion with cyclophosphamide and fludarabine; Cohort 2: Subjects with low NY-ESO-1 antigen expression and lymphodepletion with cyclophosphamide and fludarabine; Cohort 3: Subjects with high NY-ESO-1 antigen expression and lymphodepletion with cyclophosphamide alone -- no fludarabine; and Cohort 4: Subjects with high NY-ESO-1 antigen expression and lymphodepletion with a modified lower dose than Cohort I of cyclophosphamide and fludarabine. In Cohort 1, the median duration of response is reported to be approximately 31 weeks as of the August 31 data cutoff. Ongoing NY-ESO SPEAR T-cell persistence has been observed for up to 36 months. In Cohort 2, four subjects of a targeted 10 are currently enrolled in the second cohort; three patients have been treated with NY-ESO SPEAR T-cells. As of August 31, best responses seen in these three patients were: one partial response, one stable disease, and one progressive disease. In Cohorts 3 and 4, five patients are currently enrolled in the third cohort; no objective responses have been observed to date. As pre-specified in the protocol, enrollment in cohort 3 has ceased, and company has initiated enrollment in Cohort 4. NY-ESO SPEAR T-cells continue to demonstrate a generally acceptable benefit:risk profile in all treated patients to date. Most common toxicities related to therapy can be monitored and managed with medical intervention and supportive care. While there are differences in the patient populations, incidence of cytokine release syndrome with NY-ESO-1c259 SPEAR T appears to be of lower frequency and severity than reported with CD19 CAR-T therapy. As previously reported at the 2016 Annual American Society of Clinical Oncology Meeting, there was one fatal SAE of bone marrow failure in Cohort 2 of the synovial sarcoma trial. Internal investigations have not identified a mechanism by which NY-ESO SPEAR T-cells may have caused bone marrow failure.

  • 09

    Oct

ADAP Adaptimmune
$6.40

-0.39 (-5.74%)

02/25/16
02/25/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Boston Scientific (BSX) initiated with a Buy at SunTrust by analyst Bruce Nudell, who expects an organic growth accelerating through 2018 driven by structural heart sales and core market stabilization. 2. Kite Pharma (KITE) initiated with a Buy, with analyst Robyn Karnauskas saying that Kite's technology could be the first to market and its data in the largest blood cancer market look similar to competition. The analyst also started Juno Therapeutics (JUNO) and Adaptimmune (ADAP) with Buy ratings. 3. Insulet (PODD) initiated with a Sell at Empire by analyst Cathy Reese, who said the company has several issues with its OmniPod System that will not be remedied with planned upgrades. 4. Biogen (BIIB) initiated with a Buy at Citi. 5. Crown Castle (CCI) initiated with a Buy at SunTrust. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/04/16
LEER
08/04/16
NO CHANGE
LEER
Outperform
Adaptimmune partial clinical hold on planned trial 'surprising,' says Leerink
Leerink analyst Michael Schmidt sees the announced partial clinical hold on Adaptimmune's liposarcoma study as "surprising" and notes that it introduces some additional risk. However, the analyst says the news does not "fundamentally" change his investment thesis on Adaptimmune as he expects a rapid resolution. Schmidt reiterates an Outperform rating on the shares.
08/26/16
SBSH
08/26/16
NO CHANGE
SBSH
Buy
Adaptimmune partial clinical hold may be lifted within weeks, says Citi
Citi analyst Robyn Karnauskas said that after traveling with several members of Adaptimmune's management team, including its CEO and CFO, she came away feeling that their TCR platform remains in the lead despite delays. The FDA's partial clinical hold in myxoid round cell liposarcoma, or MRCLS, was not related to safety or efficacy of the product and Karnauskas sees the potential for the FDA to possibly reverse the partial clinical hold within a few weeks, she tells investors. Citi keeps a Buy rating on Adaptimmune shares.
09/30/16
RAJA
09/30/16
INITIATION
Target $16
RAJA
Outperform
Adaptimmune initiated with an Outperform at Raymond James
Raymond James analyst Reni Benjamin initiated Adaptimmune with a Buy and a $16 price target saying it is a leading player in the engineered T cell receptor therapy space, with a growing product portfolio concentrating primarily in the solid tumor market.

TODAY'S FREE FLY STORIES

NUE

Nucor

$62.83

1.97 (3.24%)

15:46
02/27/17
02/27
15:46
02/27/17
15:46
Options
Nucor call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROKA

Roka Bioscience

$4.26

-0.18 (-4.05%)

15:44
02/27/17
02/27
15:44
02/27/17
15:44
Conference/Events
Roka Bioscience to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 29

    Mar

TESS

TESSCO

$14.05

-0.3 (-2.09%)

15:43
02/27/17
02/27
15:43
02/27/17
15:43
Hot Stocks
TESSCO signs deal with GEAR4 as exclusive U.S. distributor »

TESSCO Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LJPC

La Jolla

$19.87

1.65 (9.06%)

15:42
02/27/17
02/27
15:42
02/27/17
15:42
Recommendations
La Jolla analyst commentary  »

La Jolla price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 19

    Mar

CUR

Neuralstem

$3.86

0.16 (4.32%)

15:36
02/27/17
02/27
15:36
02/27/17
15:36
Hot Stocks
Breaking Hot Stocks news story on Neuralstem »

Tianjin Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WUBA

58.com

$32.46

0.49 (1.53%)

15:35
02/27/17
02/27
15:35
02/27/17
15:35
Options
58.com options imply 10.8% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

NURO

NeuroMetrix

$0.63

-0.0317 (-4.79%)

15:35
02/27/17
02/27
15:35
02/27/17
15:35
Conference/Events
NeuroMetrix to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

CGI

Celadon Group

$8.55

0.45 (5.56%)

, USAK

USA Truck

$9.00

0.14 (1.58%)

15:33
02/27/17
02/27
15:33
02/27/17
15:33
Hot Stocks
Celadon, USA Truck called best M&A targets as truckers seen consolidating »

Stephens argued that amid…

CGI

Celadon Group

$8.55

0.45 (5.56%)

USAK

USA Truck

$9.00

0.14 (1.58%)

HTLD

Heartland Express

$20.64

0.2 (0.98%)

KNX

Knight Transportation

$32.70

0.55 (1.71%)

SWFT

Swift Transportation

$22.09

0.35 (1.61%)

CVTI

Covenant Transportation

$20.06

0.05 (0.25%)

MRTN

Marten Transport

WERN

Werner

$27.80

0.45 (1.65%)

XPO

XPO Logistics

$51.41

1.01 (2.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

  • 02

    May

GLD

SPDR Gold Trust

$119.45

-0.25 (-0.21%)

15:32
02/27/17
02/27
15:32
02/27/17
15:32
Options
Aggressive short-term call spread in the SPDR Gold Fund »

Aggressive short-term…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGY

Stone Energy

$6.73

0.15 (2.28%)

, EQT

EQT Corporation

$60.73

0.785 (1.31%)

15:31
02/27/17
02/27
15:31
02/27/17
15:31
Hot Stocks
Stone Energy announces close of sale of Appalachia properties »

Stone Energy (SGY)…

SGY

Stone Energy

$6.73

0.15 (2.28%)

EQT

EQT Corporation

$60.73

0.785 (1.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXEL

Exelixis

$21.69

-0.05 (-0.23%)

15:20
02/27/17
02/27
15:20
02/27/17
15:20
Options
Exelixis options imply 12.7% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

$NSD

NASDAQ Market Internals

15:17
02/27/17
02/27
15:17
02/27/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
02/27/17
02/27
15:16
02/27/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$29.94

-0.25 (-0.83%)

15:14
02/27/17
02/27
15:14
02/27/17
15:14
Periodicals
GE sales process for Industrial Solutions may start in March, Bloomberg says »

Amid its continuing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

VIP

VimpelCom

$4.30

-0.04 (-0.92%)

15:11
02/27/17
02/27
15:11
02/27/17
15:11
Options
Higher option volume in Vimpel driven by poste-earnings puts »

Higher option volume in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VAC

Marriott Vacations

$96.51

-2.39 (-2.42%)

15:09
02/27/17
02/27
15:09
02/27/17
15:09
Conference/Events
Marriott Vacations management to meet with MKM Partners »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

TGT

Target

$66.95

0.435 (0.65%)

, AZO

AutoZone

$734.44

1.685 (0.23%)

15:06
02/27/17
02/27
15:06
02/27/17
15:06
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

TGT

Target

$66.95

0.435 (0.65%)

AZO

AutoZone

$734.44

1.685 (0.23%)

DPZ

Domino's Pizza

$185.90

-0.378 (-0.20%)

VRX

Valeant

$16.73

0.5499 (3.40%)

PAH

Platform Specialty Products

$13.19

0.14 (1.07%)

ENDP

Endo

$13.15

-0.24 (-1.79%)

DDD

3D Systems

$17.04

0.55 (3.34%)

SEAS

SeaWorld

$18.66

0.035 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 02

    Mar

  • 13

    Mar

  • 14

    Mar

  • 14

    Mar

  • 19

    Mar

  • 22

    Mar

  • 23

    Mar

  • 24

    Mar

PCLN

Priceline

$1,631.62

-5.64 (-0.34%)

, WDAY

Workday

$90.92

1.26 (1.41%)

15:05
02/27/17
02/27
15:05
02/27/17
15:05
Earnings
Notable companies reporting after market close »

Notable companies…

PCLN

Priceline

$1,631.62

-5.64 (-0.34%)

WDAY

Workday

$90.92

1.26 (1.41%)

PRGO

Perrigo

$84.39

-0.04 (-0.05%)

ALB

Albemarle

$92.74

-0.19 (-0.20%)

EXEL

Exelixis

$21.69

-0.05 (-0.23%)

RSPP

RSP Permian

$40.77

0.88 (2.21%)

FTR

Frontier Communications

$3.37

-0.02 (-0.59%)

CST

CST Brands

$48.37

0.02 (0.04%)

THC

Tenet

$22.36

0.365 (1.66%)

HTZ

Hertz

$19.86

-0.11 (-0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 02

    Mar

  • 13

    Mar

  • 14

    Mar

  • 16

    Mar

  • 20

    Mar

  • 21

    Mar

HTZ

Hertz

$19.87

-0.105 (-0.53%)

15:05
02/27/17
02/27
15:05
02/27/17
15:05
Options
Hertz options imply 18.0% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

15:00
02/27/17
02/27
15:00
02/27/17
15:00
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

MNK

Mallinckrodt

$54.42

1.04 (1.95%)

14:57
02/27/17
02/27
14:57
02/27/17
14:57
Conference/Events
Mallinckrodt management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 03

    Mar

INCY

Incyte

$131.21

9.26 (7.59%)

, SE

Acquired by ENB

14:55
02/27/17
02/27
14:55
02/27/17
14:55
Hot Stocks
Incyte to replace Spectra Energy in S&P 500 as of 2/28 open »

Spectra Energy (SE) is…

INCY

Incyte

$131.21

9.26 (7.59%)

SE

Acquired by ENB

ENB

Enbridge

$42.05

0.705 (1.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 06

    Mar

  • 14

    Mar

  • 01

    Apr

  • 19

    Apr

DDS

Dillard's

$56.99

-0.01 (-0.02%)

, ISIL

Intersil

14:55
02/27/17
02/27
14:55
02/27/17
14:55
Hot Stocks
Dillard's to replace Intersil in S&P 400 as of 2/28 open »

Renesas Electronics Corp.…

DDS

Dillard's

$56.99

-0.01 (-0.02%)

ISIL

Intersil

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WRK

WestRock

$53.69

0.26 (0.49%)

14:54
02/27/17
02/27
14:54
02/27/17
14:54
Conference/Events
WestRock management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

GIG

GigPeak

$3.10

0.03 (0.98%)

14:52
02/27/17
02/27
14:52
02/27/17
14:52
Hot Stocks
Gardner Lewis reports new 8.6% stake in GigPeak »

Shares of GigPeak spiked…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Apr

  • 05

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.